HPE HPE 85 – Spring 2017 - Page 27

DOLUTEGRAVIR IS M Y CORE THE ONLY INI THAT OFFERS ALL OF THE FOLLOWING: + + SUPERIOR EFFICACY HIGH BARRIER TO RESISTANCE BOOSTER-FREE DOSING in treatment-naïve patients vs Atripla ® , darunavir/r and atazanavir/r (in women) 1-3 0 resistance to dolutegravir-based regimens in treatment-naïve trials 1-5 with few clinically significant drug-drug interactions 5 Build a regimen for your patients with DOLUTEGRAVIR AT THE CORE. dolutegravir / abacavir / lamivudine dolutegravir / abacavir / lamivudine TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg. Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction. TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age. Prescribing Information Triumeq ® dolutegravir 50mg/abacavir 600mg/lamivudine 300mg tablets See Summary of Product Characteristics before prescribing. Indication: HIV in over 12 years and ≥ 40kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. Dose: one tablet once daily with or without food. Elderly: Limited data in 65+ yrs. Creatinine clearance <50ml/min or moderate/ severe hepatic impairment: Not recommended. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ "&WfW27W7V7FVB&6f"5"7FG&VWvFWBFVb5"7W7V7FVBWfW"&VG&GV6RFWFVw&f" &6f"6Fr&GV7BgFW"7W7V7FVB5"&62bVR&V7FfF7G&R7FVV7&627&V6VBvVvBƗG2vV66RF"eG2WFF0"26֖fV7F66W6fRFF&VF6&WGvVV&6f"Bԓ2RBb"R2b"2b2B"2Rr2rR"BR2W&ƗFV֖B&V6VFVBbFWFVw&f"&WV&VB"BvFWG&f&PvBWB&2FVBVfb&VWb&R&f6&2FVBB&f"6&&WR6&&WRVFV&&&FB7B( 2v'BW6RvF6G&&RB&V6VFVBW6RvFr6FrF6G266VVFfF֖2"&&WV&W2F6vR6W&F6WFvFWFf&֖㠦F"&VgV7FB66FW"WFf&֖F6RFW7FVB&Vv77FFB&V6VFVBfB'&V7BfVVFr6FRVffV7G36VR52f FWF2VF6R66VWG&VF6&FW'2tF7GW&&6RfFwVRW'6V6FfG&WFW&W76FW726V6RWF&w6R6Vv67F2&6'W&GW2V6'F&vW66RF6&FW'27FVfWfW"VWfF2bB5BB5&BG67&627V6FFVF"7V6FRGFVB&&FזǗ627F26F62W'FVVFf&R7FWfV2Ф67G&RF2WFW&V7&Ǘ62&62267G33F&WG3 *3s`URBCFW#fbVF6&RTFBw&VBvW7B&B'&VFf&B֖FFW6WEsu2gW'FW"f&F2f&Rg&7W7FW"6F7B6VG&Rv6֗FƖRTFB7F6W&vW7BW'&FvR֖FFW6WT#%BХG&VW2&Vv7FW&VBG&FV&bFRfbVF6&Rw&Wb6W0FFRb&fâVǒ#`26FSTE$3rBRFf6 *FWFVw&f"SrF&WG06VR7V'b&GV7B6&7FW&7F72&Vf&R&W67&&pF6Fb"V'2B(RCr2'Bb6&FFW&F6sSr6PFǒvF"vFWBfBb&fV7W7V7FVBFVw&6R&W67F6RSrGv6RFǐvFVff&VWf&RF&f"&Ff"WG&f&RvFWB&7FVB6&&WR6&&WRVFV&&&F7B( 2v'B"&f6GVG2vF&fV7W7V7FVBFVw&6R&W67F6SSrGv6RFǒ&VfW&&ǒvFfBRBR"Ɩ֗FVBFFcR'26WF6WfW&RWF2&VB6G&F6F3W'6V6FfGFw&VFVB6F֖7G&FvFFfWFƖFRv&w2&V6WF3&6bW'6V6FfG&V7F2F66FVRFWFVw&f"@FW"7W7V7BvVG2VFFVǒb7W7V7FVB&62b7FVV7&62VP&V7FfF7G&RF"eG2WFF2"26֖fV7FBV7W&RVffV7FfPWFF2"FW&6WFvFWFf&֖F"&VgV7FB66FW WFf&֖F6RFW7FVBW6RvFWG&f&R&WV&W2&7FVB"7&V6VBF6R`FWFVw&f"W6RvFr6FrF6G266VVFfF֖2"&&WV&W0F6vR6W&F&Vv77FFB&V6VFVBfB'&V7BfVVFr6FRVffV7G36VR52f"gVFWF2VF6RtF7GW&&6R6&&G&V2FW&W76FW72&6'W&GW2fFwVRVWfF2bB5BB5W'6V6FfG7V6FFVF"7V6FRGFVB&62267G33F&WG2 *3CsPUR2"FW#fbVF6&RTFBw&VBvW7B&B'&VFf&B֖FFW6WEsu2gW'FW"f&Ff&Rg&7W7FW"6F7B6VG&Rv6֗FƖRTFB7F6W&vW7BW'&FvR֖FFW6WT#%BХ3Ff62&Vv7FW&VBG&FV&bFRfbVF6&Rw&Wb6W0FFRb&fâ7F&W"#`26FSTDrSR2&VfW&V6W3v6W2WB7V"VRFVf27G"#SsRSRS"ƖWB6WB`b#S"BS#rS3b2'&V2WB&W6VFVBCVFW&FE26fW&V6SVǒ#"#cGW&&6WFg&6'7G&7BD##T"B&ffbWB6WBfV7BF2#32#rӓ3RRDd4FWFVw&f"7V'b&GV7B6&7FW&7F726WFV&W"#RGfW'6RWfVG26VB&R&W'FVBf"FRT&W'Frf&2Bf&F6&RfVBBwwrև&vbVVv6&BGfW'6RWfVG26VB6&R&W'FVBFv6֗FƖR##CCGfW'6RWfVG26VB&R&W'FVBf"&VBGfW'6RWfVG26VB&R&W'FVBF&V7FǒFFR$g&VW7B&6fv6R6V7FVF&GV7G2&VwVF'WF&GV&6f'BFW'&6RGV&Ɩ"FVâ3S2csbCsVG6fWG&RGfW'6RWfVG26VB6&R&W'FVBFv6֗FƖR#CB#SRE$TUBDd4&R&Vv7FW&VBG&FV&2bFRfbVF6&Rw&Wb6W2*#bfbVF6&Rw&Wb6W2&vG2&W6W'fVBFFRb&W&FfV&W"#bdbDu"sfP